BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18030131)

  • 1. Relationship between radioactive iodine therapy for thyroid carcinoma and nasolacrimal drainage system obstruction.
    Cetinkaya A; Kersten RC
    Ophthalmic Plast Reconstr Surg; 2007; 23(6):496. PubMed ID: 18030131
    [No Abstract]   [Full Text] [Related]  

  • 2. Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients.
    Morgenstern KE; Vadysirisack DD; Zhang Z; Cahill KV; Foster JA; Burns JA; Kloos RT; Jhiang SM
    Ophthalmic Plast Reconstr Surg; 2005 Sep; 21(5):337-44. PubMed ID: 16234694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lacrimal drainage system obstruction associated to radioactive iodine therapy for thyroid carcinoma].
    Fonseca FL; Lunardelli P; Matayoshi S
    Arq Bras Oftalmol; 2012; 75(2):97-100. PubMed ID: 22760799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salivary gland dysfunction and nasolacrimal duct obstruction: stenotic changes following I-131 therapy.
    Savage MW; Sobel RK; Hoffman HT; Carter KD; Finkelstein MW; Shriver EM
    Ophthalmic Plast Reconstr Surg; 2015; 31(3):e50-2. PubMed ID: 24836449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma.
    Kloos RT; Duvuuri V; Jhiang SM; Cahill KV; Foster JA; Burns JA
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5817-20. PubMed ID: 12466391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasolacrimal obstruction secondary to I(131) therapy.
    Burns JA; Morgenstern KE; Cahill KV; Foster JA; Jhiang SM; Kloos RT
    Ophthalmic Plast Reconstr Surg; 2004 Mar; 20(2):126-9. PubMed ID: 15083081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma.
    Shepler TR; Sherman SI; Faustina MM; Busaidy NL; Ahmadi MA; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2003 Nov; 19(6):479-81. PubMed ID: 14625496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoscopic dacryocystorhinostomy following radioactive iodine thyroid ablation.
    Van Tassel SH; Segal KL; Hsu NM; Kacker A; Lelli GJ
    Orbit; 2017 Apr; 36(2):59-63. PubMed ID: 28388347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visualization of nasolacrimal drainage system after radioiodine therapy in patients with thyroid cancer.
    Sakahara H; Yamashita S; Suzuki K; Imai M; Kosugi T
    Ann Nucl Med; 2007 Nov; 21(9):525-7. PubMed ID: 18030585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Demographic Characteristics of Tearing in Patients after Radioiodine Ablation for Differentiated Thyroid Cancer.
    Yartsev VD; Solodkiy VA; Fomin DK; Borisenko TE; Atkova EL
    Curr Eye Res; 2021 Sep; 46(9):1320-1324. PubMed ID: 33455422
    [No Abstract]   [Full Text] [Related]  

  • 11. Nasolacrimal duct obstruction as a complication of iodine-131 therapy in patients with thyroid cancer.
    Fard-Esfahani A; Farzanefar S; Fallahi B; Beiki D; Saghari M; Emami-Ardekani A; Majdi M; Eftekhari M
    Nucl Med Commun; 2012 Oct; 33(10):1077-80. PubMed ID: 22825036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Associated With Radioactive Iodine Therapy-Acquired Nasolacrimal Duct Obstruction.
    Lee IT; Chen W; Chen Q; Cole HA; Bischoff LA; Jessop AC; Sobel RK
    Endocr Pract; 2022 Dec; 28(12):1210-1215. PubMed ID: 35970353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical Risk Prediction for Nasolacrimal Duct Obstruction in Radioactive Iodine-Treated Thyroid Cancer: A Nationwide Cohort Study.
    Lee JY; Woo KI
    Thyroid; 2022 May; 32(5):544-551. PubMed ID: 34894720
    [No Abstract]   [Full Text] [Related]  

  • 14. Dependence of radioactive iodine-131 capture by the lacrimal ducts on the tear production level.
    Yartsev VD; Sheremeta MS; Trukhin AA; Atkova EL; Degtyarev MV; Yasyuchenya VS; Yudakov DV
    Indian J Ophthalmol; 2023 May; 71(5):1828-1832. PubMed ID: 37203037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topographic and anatomical features of the nasolacrimal duct obstruction due to radioiodine treatment.
    Yartsev VD; Atkova EL; Ekaterinchev MA
    Int Ophthalmol; 2023 Sep; 43(9):3385-3390. PubMed ID: 37199817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epiphora after radioactive iodine ablation for thyroid cancer.
    Sun GE; Hatipoglu B
    Thyroid; 2013 Feb; 23(2):243-5. PubMed ID: 22946448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accumulation of 131Iodine in the nasolacrimal sac/duct after radioiodine therapy for papillary thyroid cancer.
    Usmani S; Jain A; Al-Riyami K; Abubakar S
    J Pak Med Assoc; 2023 Mar; 73(3):713-714. PubMed ID: 36932793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nasolacrimal drainage obstruction after radioiodine therapy: case report and a review of the literature.
    Brockmann H; Wilhelm K; Joe A; Palmedo H; Biersack HJ
    Clin Nucl Med; 2005 Aug; 30(8):543-5. PubMed ID: 16024949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary Acquired Nasolacrimal Duct Obstruction as a Specific Complication of Treatment With Radioactive Iodine (Morphological Study).
    Fedorov AA; Atkova EL; Yartsev VD
    Ophthalmic Plast Reconstr Surg; 2020; 36(3):250-253. PubMed ID: 31743278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Na+/I- symporter expression, function, and regulation in non-thyroidal tissues and impact on thyroid cancer therapy.
    Jhiang SM; Sipos JA
    Endocr Relat Cancer; 2021 Sep; 28(10):T167-T177. PubMed ID: 33974556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.